Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation (HCT) Meeting Abstract
| Authors: | Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M.; Gooptu, M.; Bin, C.; Deeg, J.; Gallacher, P.; Wennborg, A.; Kaylor Hickman, D.; Attar, E. C.; Fernandez, H. F. |
| Abstract Title: | Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation (HCT) |
| Meeting Title: | 2022 Tandem Meetings of ASTCT and CIBMTR |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 28 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2022 Apr 23-26 |
| Meeting Location: | Salt Lake City, UT |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-03-01 |
| Start Page: | S34 |
| End Page: | S35 |
| DOI: | 10.1016/S2666-6367(22)00200-7 |
| PROVIDER: | manual |
| Notes: | Abstract: 39 -- Located within the section named "Oral Abstract - Session E - Acute And Chronic Leukemia" |
